menu search

ESAIY / Upside for Japanese pharma firm Eisai is still 'very, very strong,' says financial services firm

Upside for Japanese pharma firm Eisai is still 'very, very strong,' says financial services firm
Jesper Koll of Monex Group says Eisai is "not a defensive play" and it's "turning into a growth play." Read More
Posted: Jun 8 2023, 01:13
Author Name: CNBC International TV
Views: 111950

ESAIY News  

Alzheimer's medication: Eisai reporting positive data on injectable drug

By Yahoo Finance
October 28, 2023

Alzheimer's medication: Eisai reporting positive data on injectable drug

This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their Alzheimer's drug- Leqembi. more_horizontal

Merck and Eisai say two lung-cancer trials failed to meet their main goals

By Market Watch
September 22, 2023

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet thei more_horizontal

The 3 Best Biotech Stocks to Buy Now: September 2023

By InvestorPlace
September 4, 2023

The 3 Best Biotech Stocks to Buy Now: September 2023

Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF more_horizontal

Merck and Eisai cull late-stage study for head and neck cancer therapy

By Proactive Investors
August 25, 2023

Merck and Eisai cull late-stage study for head and neck cancer therapy

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head more_horizontal

Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

By Market Watch
August 25, 2023

Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer fail more_horizontal

Merck, Eisai discontinue late-stage study for cancer therapy

By Reuters
August 25, 2023

Merck, Eisai discontinue late-stage study for cancer therapy

Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and more_horizontal

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes

By InvestorPlace
July 30, 2023

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes

The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the more_horizontal

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

By PRNewsWire
July 11, 2023

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the more_horizontal


Search within

Pages Search Results: